Achembio's pipeline consists of three innovative small molecular drugs-ACH251, ACH252, and ACH253, which are discovered based on a novel approach targeting the inhibition of HIF-1α in the development of antifibrotic agents. To find a treatment for IPF, we screened over 1,500 compounds that target underlying disease pathogenesis and In these virtual screening and screening assays campaign three compounds (BCC, BCT and BGC) were identified as promising therapeutic potentials.

As a result of animal studies, oral combo therapy of BCC and BCT showed optimal results and Achembio recently succeeded in chemical synthesis of the two compounds to be a new chemical entity, ACH251. Currently efficacy and safety of ACH251 as a new substances is being verified.

ACH252 is a repurposed drug candidate for new IPF application. BGC(Guaiacol) was originally developed for other indications. ACH252, inhaled formulation of Guaiacol allows it to be delivered directly into the lung tissues and showed excellent therapeutic effects compared with oral dosing in animal studies. Since Its safety and pharmacokinetics already have been evaluated in clinical trials, the company intends to move the drug directly into preclinical trial.

ACH253 is a new chemical entity designed and synthesized by researchers at Achembio for the treatment of cancer related IPF. The efficacy and safety of ACH253 are currently being verified.

Achembio’s experienced research and development team is rapidly advancing the candidates for the treatment of IPF and other pipeline candidates for IPF and other severe fibrosis diseases such as diabetic kidney Disease (DKD), non-alcoholic fatty liver disease (NASH) and systemic sclerosis(SSc).